Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Moderate Buy” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.13.

STRO has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th. Wells Fargo & Company dropped their price objective on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. JMP Securities reiterated a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th.

Sutro Biopharma Stock Up 2.9 %

STRO opened at $1.79 on Tuesday. The firm has a market capitalization of $147.60 million, a P/E ratio of -1.11 and a beta of 1.15. The firm’s 50 day moving average is $1.94 and its 200-day moving average is $3.06. Sutro Biopharma has a 52-week low of $1.51 and a 52-week high of $6.13.

Institutional Trading of Sutro Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Gladius Capital Management LP bought a new stake in shares of Sutro Biopharma in the third quarter worth $28,000. Dynamic Technology Lab Private Ltd acquired a new position in Sutro Biopharma in the fourth quarter worth $26,000. China Universal Asset Management Co. Ltd. acquired a new position in Sutro Biopharma in the fourth quarter worth $32,000. Virtu Financial LLC acquired a new position in Sutro Biopharma in the third quarter worth $77,000. Finally, Vontobel Holding Ltd. boosted its holdings in Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.